Independent Director, Chairman of the Clinical Development Committee Jean-Yves Blay is Professor of Medical Oncology and has been General Director of the Léon Bérard Center in Lyon since 2014. He holds a PhD obtained in 1994 from the Claude Bernard University in Lyon and has been authorized to supervise research since 1996. He currently leads… Continue reading Prof. Jean-Yves Blay
Author: alcyon
Dr. Alessandro Riva
Chairman and CEO Dr. Riva has nearly 30 years’ experience in the Life Sciences industry. He was CEO of Intima Bioscience which specializes in cell therapies for solid cancers and was previously CEO of Ichnos Sciences. Dr Riva was also Executive Vice President (EVP), Global Head of Oncology Therapeutics and Cell & Gene Therapy at… Continue reading Dr. Alessandro Riva
Ethics and compliance
Transgene, in the conduct of its activities, aims to act with integrity and in full compliance with its regulatory and legal environment. Transgene has set up a compliance program addressing business ethics, the protection of personal data and including specific tools, such as a whistleblowing system. The Internal Audit department of Institut Mérieux, Transgene’s parent company,… Continue reading Ethics and compliance
Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform
Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform
Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine
Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine
annonceHomeUS
TG4050First positive data from Phase I clinical trials Press release [PDF] Initial data presented at the ASCO congress (June 2022) Interview of the team and Pr Ottensmeier on the data (November 2022)
Regulated information
Monthly information on shares outstanding and voting rights (in French) 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Share buyback program (in French) Descriptif du programme de rachat d’actions autorisé par l’assemblée générale mixte des actionnaires du 24 mai 2016 Liquidity contract related information Implementation of the liquidity agreement Half-year report… Continue reading Regulated information
annonce substitut
A particularly innovative immunotherapy, TG4050 is the lead myvac® candidate. This individualized treatment is based on the specific mutations that are identified in each patient’s tumor. TG4050 video
annonce
One cancer, one patient, one vaccine With TG4050, Transgene is developing an individualized immunotherapy based on advanced genetic engineering and artificial intelligence (AI) technologies. The treatment is based on an optimized MVA viral vector. myvac® video Each treatment is designed and manufactured by Transgene for each patient, targeting the most relevant tumor targets (cancer-specific neoantigens)… Continue reading annonce
Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021
20211109 – Transgene BioInvent SITC BT-001 en